Literature DB >> 30622782

A surveillance method-oriented detection of post-operative spatial-temporal recurrence for non-small cell lung cancer.

Jun-Jie Xi1, Jia-Cheng Yin1, Lin Wang1, Chun-Lai Lu1, Qun Wang1, Wei Jiang1.   

Abstract

BACKGROUND: This study evaluated spatial-temporal recurrence patterns after curative resection for non-small cell lung cancer (NSCLC) to clarify and recommend appropriate post-operative surveillance.
METHODS: A total of 2,486 consecutive patients between January 2005 and December 2012 with NSCLC (stage I-IIIA) who underwent definitive surgical resection were retrospectively analyzed. We used a hazard rate curve to evaluate event dynamics. Disease-free survival (DFS) was evaluated by the Kaplan-Meier method. Univariate and multivariate analyses with Cox proportional hazards regression identified risk factors that predicted DFS.
RESULTS: The median follow-up was 50.1 months. Recurrences were diagnosed in 852 (34.3%) patients. Four hundred eighty-nine events first occurred in the chest, 177 in the brain, 117 in the bone, and 71 in the abdomen. Of all recurrences, 78.5% occurred in the first 3 years. Univariate and multivariate analyses identified the age at diagnosis (P<0.001), histology (P=0.023), tumor size (P<0.001), pathologic N stage (P<0.001), and grade (P=0.043) as independent risk factors for intra-thoracic recurrences. Histology (P<0.001), tumor size (P<0.001), surgical method (P=0.021), pathologic N stage (P<0.001), and grade (P=0.005) were independent to predict extra-thoracic recurrences. The hazard rate curve displayed an initial surge of time to any treatment failure during 12 months after surgery. Based on sub-group analysis, both intra- and extra-recurrences increased with stage and brain recurrences in stage IIIA occurred earlier than stage II. Hazard rate curve of brain recurrences in squamous cell carcinoma showed a moderate peak during 9-15 months. Hazard rate curves of brain and bone recurrences in adenocarcinoma displayed clear peaks at 9-27 and 15-30 months, respectively.
CONCLUSIONS: Intra- and extra-thoracic recurrences correlate with different clinicopathological factors. Brain MRI and bone ECT were recommended for selected patients in particular time to early detect extra-thoracic recurrences.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); post-operative; recurrence dynamic; surveillance

Year:  2018        PMID: 30622782      PMCID: PMC6297423          DOI: 10.21037/jtd.2018.10.32

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  19 in total

1.  Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.

Authors:  Robert C Doebele; Xian Lu; Christopher Sumey; Delee A Maxson; Andrew J Weickhardt; Ana B Oton; Paul A Bunn; Anna E Barón; Wilbur A Franklin; Dara L Aisner; Marileila Varella-Garcia; D Ross Camidge
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

2.  [IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer].

Authors:  V Westeel; M P Lebitasy; M Mercier; P Girard; F Barlesi; F Blanchon; J Tredaniel; P Bonnette; M C Woronoff-Lemsi; J L Breton; R Azarian; P E Falcoz; S Friard; L Geriniere; S Laporte; E Lemarie; E Quoix; G Zalcman; J Guigay; F Morin; B Milleron; A Depierre
Journal:  Rev Mal Respir       Date:  2007-05       Impact factor: 0.622

3.  Stage I lung cancer survivorship: risk of second malignancies and need for individualized care plan.

Authors:  Rakesh Surapaneni; Priya Singh; Kumar Rajagopalan; Alexandre Hageboutros
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

Review 4.  What is the most effective follow-up model for lung cancer patients? A systematic review.

Authors:  Mia Schmidt-Hansen; David R Baldwin; Elise Hasler
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

5.  Follow-up in lung cancer: how often and for what purpose?

Authors:  R N Younes; J L Gross; D Deheinzelin
Journal:  Chest       Date:  1999-06       Impact factor: 9.410

6.  Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients.

Authors:  Brent A Williams; Hiroshi Sugimura; Chiaki Endo; Francis C Nichols; Stephen D Cassivi; Mark S Allen; Peter C Pairolero; Claude Deschamps; Ping Yang
Journal:  Ann Thorac Surg       Date:  2006-03       Impact factor: 4.330

7.  The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: Experiences at a single institution.

Authors:  Yoshikane Yamauchi; Thomas Muley; Seyer Safi; Stefan Rieken; Helge Bischoff; Jutta Kappes; Arne Warth; Felix J F Herth; Hendrik Dienemann; Hans Hoffmann
Journal:  Lung Cancer       Date:  2015-09-15       Impact factor: 5.705

8.  Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients.

Authors:  Chris R Kelsey; Lawrence B Marks; Donna Hollis; Jessica L Hubbs; Neal E Ready; Thomas A D'Amico; Jessamy A Boyd
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

9.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Authors:  Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

10.  Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control.

Authors:  Jason P Sheehan; Ming-Hsi Sun; Douglas Kondziolka; John Flickinger; L Dade Lunsford
Journal:  J Neurosurg       Date:  2002-12       Impact factor: 5.115

View more
  1 in total

1.  Prognostic value of an immunohistochemical signature in patients with pulmonary squamous cell carcinoma undergoing complete surgical resection.

Authors:  Chengbin Lin; Yong Xi; Hongyan Yu; Xiaohan Chen; Weiyu Shen
Journal:  J Thorac Dis       Date:  2022-02       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.